Mediolanum International Funds’s Neurocrine Biosciences NBIX Stock Holding History

Mediolanum International Funds’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.13M	Buy	24,293 +14,199	+141%	+$2.11M	0.04%	299
2026 Q1	$1.3M	Sell	10,094 -41,312	-80%	-$5.48M	0.01%	372
2025 Q4	$7.25M	Buy	51,406 +48,032	+1,424%	+$6.96M	0.07%	245
2025 Q3	$473K	Sell	3,374 -15,811	-82%	-$2.14M	0.01%	402
2025 Q2	$2.41M	Sell	19,185 -38,531	-67%	-$4.42M	0.03%	315
2025 Q1	$6.53M	Buy	57,716 +1,372	+2%	+$174K	0.09%	218
2024 Q4	$7.7M	Sell	56,344 -3,558	-6%	-$440K	0.1%	186
2024 Q3	$6.88M	Buy	59,902 +13,809	+30%	+$1.89M	0.1%	208
2024 Q2	$5.78M	Buy	46,093 +36,289	+370%	+$4.98M	0.09%	201
2024 Q1	$1.35M	Buy	+9,804	New	+$1.34M	0.02%	324

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Mediolanum International Funds's NBIX Position: Q2 2026 in Review

Mediolanum International Funds increased its Neurocrine Biosciences (NBIX) stake by 141% in Q2 2026, buying an estimated $2.11M and bringing the position to 24,293 shares worth $4.13M. The position accounts for 0.04% of the portfolio, ranked #299.

Mediolanum International Funds first reported a position in NBIX in Q1 2024 and has held it in 10 quarters since. The position peaked at $7.7M in Q4 2024. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Mediolanum International Funds held 24,293 shares of Neurocrine Biosciences worth $4.13M as of Q2 2026.
Mediolanum International Funds bought 14,199 Neurocrine Biosciences shares in Q2 2026, an estimated $2.11M.
Neurocrine Biosciences made up 0.04% of Mediolanum International Funds's portfolio in Q2 2026, its #299 holding.
Mediolanum International Funds first reported a position in Neurocrine Biosciences in Q1 2024 and has held it in 10 quarters since.
Mediolanum International Funds's Neurocrine Biosciences position peaked at $7.7M in Q4 2024.
781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Mediolanum International Funds's 13F filing for Q2 2026, filed 23 Jul 2026.